Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6052W HIGH $8.50
Volume
4.52 K
Value Traded
149.83 K
Short % Float
1.66%
Days to Cover
5.0
-2.17%Week
-13.79%1 Month
-14.45%3 Month
-65.54%6 Month
-95.97%5 Year
-95.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
32.79 M
EPS (TTM)
-1.40
P/E Ratio
-
Ent. Value
33.41 M
Total Shares
14.64 M
Float Shares
11.45 M
Insiders
21.76%
Institutions
22.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
QTI Catalyst Timeline
Dated clinical, regulatory and corporate events for QT Imaging Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for QT Imaging Holdings, Inc.
5Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 5
▲Other Regulator MilestoneEx-US Regulatory
Israeli Ministry of Health grants registration for QT Imaging scanner
breast health imagingsource ↗
▲Corporate ApprovalCorporate
Stockholders approved election of Professor Zeev Weiner and Bryan Timm as Class II directors
●Timing GuidancePresentation
Company plans to file Annual Meeting results on Form 8-K with SEC
Past FDA Catalysts and PDUFA Decisions
How QTI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
QT Imaging Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QTI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Weiner ZeevDirector | Grant/Award | 3,500 55,093 held | $0.00 | 03/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QTI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in QTI for Q2 2026. | ||||
Ownership Trends
QTI Short Interest
Shares sold short, counted twice a month.
1.66%
Short % of Float
of tradable shares sold short
189.7K
Shares Sold Short
-26.9% vs prior count
5.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
38.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QTI ranks across every disease it competes in
Competitive Position is a premium feature
See how QTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQTI News
QTI▲ +4.7%today
QT Imaging to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
QT Imaging Holdings, Inc. will report its third quarter financial results on November 10, 2026. The report will follow the market close, with a conference call scheduled for 4:30 p.m. Eastern Time. The company focuses on innovative, radiation-free imaging technology for breast health management.
Read more →QTIQT Imaging’s Breast Acoustic CT™ Scanner Now Available Through National Group Purchasing Agreement with Premier
QT Imaging Holdings, Inc. has announced that its Breast Acoustic CT™ scanner is now available through a national group purchasing agreement with Premier, Inc. This partnership, facilitated by NXC Imaging, aims to enhance the distribution of this innovative, radiation-free imaging technology for breast health management. The agreement is expected to improve accessibility for healthcare providers.
Read more →QTIQT Imaging Announces CPT® Category III Code for 3D Breast Acoustic Imaging Now Effective
QT Imaging Holdings, Inc. has announced the effective date of CPT Category III code 1079T for its 3D breast acoustic imaging technology. This code will be applicable for services starting October 1, 2026, which is three months earlier than initially anticipated. This development marks a significant step in the company's efforts to enhance breast health management.
Read more →QTI▲ +5.3%on this newsshared move
QT Imaging to Ring the Nasdaq Closing Bell on October 2 in Recognition of Breast Cancer Awareness Month
QT Imaging Holdings, Inc. will celebrate Breast Cancer Awareness Month by having CEO Dr. Raluca Dinu ring the Nasdaq Closing Bell on October 2, 2026. This event aims to raise awareness about breast health and the company's innovative, radiation-free imaging technology. The ceremony will include the executive leadership and team members of QT Imaging.
Read more →QTIQT Imaging to be Honored at Premier’s Annual Supplier Innovation Celebration
QT Imaging Holdings, Inc. will be honored at Premier's annual Supplier Innovation Celebration during the 2026 Breakthroughs Conference and Exhibition. The event, scheduled for October 6-8, 2026, acknowledges groundbreaking healthcare technologies. QT Imaging is recognized for its commitment to transforming breast health management with its radiation-free imaging technology.
Read more →QTIQT Imaging Appoints Imaging Industry Veteran Dr. Mark Winkler as Chief Medical Officer
QT Imaging has appointed Dr. Mark Winkler as Chief Medical Officer. Dr. Winkler is recognized for his extensive experience as a radiologist and entrepreneur in the imaging sector. His leadership is expected to enhance the company's innovative approach to breast health management through radiation-free imaging solutions.
Read more →QTIQT Imaging to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference
QT Imaging Holdings, Inc. will participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 15-16, 2026. CFO Jay Jennings is scheduled to present on September 15 at 3:30 pm ET. This event highlights the company's commitment to advancing breast health management through its radiation-free imaging technology.
Read more →QTI▲ +7.8%on this news
QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders
QT Imaging Holdings, Inc. has released a mid-year 2026 letter to shareholders from CEO Dr. Raluca Dinu. The letter highlights the company's focus on transforming breast health management through innovative imaging technology. The CEO expresses enthusiasm about the company's achievements and aims to keep shareholders informed about future developments.
Read more →QTI▼ -5.3%on this newsshared move
QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale
QT Imaging Holding, Inc. reported a significant increase in revenue for the second quarter of 2026, more than doubling compared to the previous year. The company highlighted its ongoing execution and the strengthening of its commercial presence in the breast health management sector. QT Imaging continues to focus on innovative imaging technology that is radiation-free.
Read more →QTIQT Imaging to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026
QT Imaging Holdings, Inc. will report its second quarter financial results for 2026 on August 12, 2026, after market close. The company, known for its radiation-free breast imaging technology, will also host a conference call at 4:30 p.m. ET to discuss the results. Participants are encouraged to pre-register for the call.
Read more →QTIQT Imaging Advances Direct U.S. Commercial Strategy to Accelerate Adoption of its Breast Acoustic CT Scanner with Two Key Hires
QT Imaging Holdings, Inc. has appointed Jason Dyer and Dave Reinhart as Vice Presidents of Regional Sales for the East and West, respectively. This strategic move aims to enhance the company's direct U.S. commercial efforts for its Breast Acoustic CT Scanner. The appointments are expected to accelerate the adoption of this innovative, radiation-free imaging technology.
Read more →QTIQT Imaging Appoints Medical Imaging and Digital Health Executive Dr. Julia Albright as Chief Science Officer
QT Imaging Holdings, Inc. has appointed Dr. Julia Albright as Chief Science Officer, effective July 27, 2026. Dr. Albright brings over 25 years of experience in medical imaging, digital health, and oncology. Her expertise is expected to enhance the company's focus on transforming breast health management through innovative imaging technology.
Read more →QTIQT Imaging Holdings Announces Results of 2026 Annual Stockholder Meeting
QT Imaging Holdings announced the results of its 2026 Annual Stockholder Meeting, where stockholders voted to approve the election of Professor Zeev Weiner and Bryan Timm as Class II directors. This decision reflects the company's commitment to leadership and innovation in breast health management through advanced imaging technology.
Read more →QTIQT Imaging Receives Israeli Ministry of Health Regulatory Registration
QT Imaging Holdings, Inc. has received regulatory registration from the Israeli Ministry of Health for its innovative, radiation-free breast imaging scanner. This approval authorizes the company to commercialize the system in Israel until February 2, 2028. The registration is supported by the company's existing clearance from the U.S. FDA.
Read more →QTIQT Imaging Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations
QT Imaging has successfully completed its first FDA routine inspection without receiving any Form 483 observations. This achievement highlights the company's commitment to maintaining high operational standards and compliance with regulatory requirements. The positive outcome of the inspection may enhance QT Imaging's credibility in the biopharma industry.
Read more →QTIQT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week
QT Imaging's CEO presented the Sports Shiftmaker Award to tennis champion and breast cancer survivor Martina Navratilova during Wimbledon week. This event underscores the intersection of sports and health awareness, celebrating Navratilova's achievements and resilience. The recognition emphasizes QT Imaging's commitment to promoting health initiatives in the sports community.
Read more →QTIA New Standard of Reproducibility for Quantitative Biomarkers in Breast Imaging
The article discusses advancements in the reproducibility of quantitative biomarkers in breast imaging. It highlights the importance of these developments for improving diagnostic accuracy. However, specific details about the methodologies or results are not provided in the text.
Read more →QTI▼ -7.4%on this news
QT Imaging Receives Saudi Arabia FDA Regulatory Clearance
QT Imaging has successfully obtained regulatory clearance from the Saudi Arabia FDA. This milestone is expected to bolster the company's operations and market reach in the region, potentially leading to increased business opportunities. The approval signifies a step forward for QT Imaging in expanding its influence in the Middle Eastern healthcare market.
Read more →QTIQT Imaging Set to Join the Russell Microcap® Index
QT Imaging has announced its inclusion in the Russell Microcap® Index. This index is known for representing small-cap companies in the U.S. equity market. The move is expected to enhance visibility and attract potential investors to the company.
Read more →QTIQT Imaging Holdings Announces Closing of $10 Million Underwritten Public Offering
QT Imaging Holdings has announced the successful closing of a $10 million underwritten public offering. This financial move is expected to bolster the company's resources for future projects. Details regarding the use of proceeds and investor interest were not disclosed in the announcement.
Read more →About QT Imaging Holdings, Inc.
Headquarters3 HAMILTON LANDING, NOVATO, CA, 94949
BIOPHARMAWATCH ELITE PLUS
Trade the next QTI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime